University of California, San FranciscoSan San Francisco United States
Chronic migraine is a disabling disorder that affects millions of individuals worldwide, and may result from traumatic brain injury. The purpose of this study was to use rodent models of basic migraine mechanisms to characterize new potential treatments for chronic migraine. The scope of the research was to investigate multiple novel potential drug treatments on migraine-related brain excitability, pain-sensing mechanisms, and behavior. The major outcomes of the research were the development of a platform of assays for migraine drug screening, and the identification of new potential therapies. Specifically, we found that the acid sensing ion channel inhibitor amiloride inhibited cortical spreading depression, trigeminovascular activation, and migraine-related hyperalgesia. We also found that delta opioid receptor agonists inhibited spreading depression and migraine related hyperalgesia. Memantine inhibited cortical spreading depression, but did not inhibit trigeminovascular activation or hyperalgesia. Our studies thus identified amiloride and other acid sensing ion channel inhibitors, and delta opioid receptor agonists, as promising candidates for clinical trials as migraine treatments.